ReviewJournal of bacteriology2026
Aminopeptidase M17 in bacteria: insights into structure, function, and potential as a drug target.
Review in Journal of bacteriology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Leucyl-aminopeptidase (LAP) is a type of protease that targets peptides and the nitrogen terminus of protein molecules, playing a key role in the removal of amino acids. This function is not only significant but also enlightening, as it contributes to our understanding of microbial survival and persistence. The presence of M17-LAPs enzymes across various bacterial species indicates the possibility of creating selective inhibitors, offering new avenues for antimicrobial development amidst increasing antibiotic resistance. Additionally, understanding the relationship between the structure of these enzymes and their functions can aid in the development of more effective treatment methods and enhance current therapies. In this review, we unravel the structural blueprints, functional roles, and therapeutic promise of M17-LAPs, highlighting their relevance in the era of escalating antibiotic resistance. We also highlight future research avenues, emphasizing structural biology and protein-protein interaction mapping as keys to unlocking targeted therapeutic strategies. By bridging molecular structure with translational potential, we propose a new vision: harnessing the vulnerabilities of M17-LAPs to inspire next-generation antibacterial strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.